🟢 Cabaletta Bio is trading 10.1% up today as biotech stocks rally on positive melanoma-vaccine results

Cabaletta Bio is trading 10.1% up at $3.21, primarily as a biotech-sector rally lifts clinical-stage biotech stocks.

• No new company-specific announcement was identified on August 19, 2026.
• Moderna and Merck reported positive Phase 3 melanoma-vaccine results, including improved recurrence-free survival.
• The broader biotechnology ETF is up 3.73%, supporting stronger risk appetite across clinical-stage biotech stocks.